Table 4 Cox regression hazard model including the maximum grade of total adverse events within the first 6 months for relapse-free survival.

From: Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials

 

Univariable

Multivariable

Characteristics

HR

95% CI

P

HR

95% CI

P

Adverse events

 Grade 0

1 (Reference)

  

1 (Reference)

  

 Grade 1

0.73

(0.62–0.87)

0.0004

0.73

(0.62–0.87)

0.0004

 Grade 2

0.72

(0.62–0.85)

<0.0001

0.73

(0.62–0.86)

0.0001

 Grade 3

0.67

(0.56–0.81)

<0.0001

0.67

(0.56–0.82)

<0.0001

 Grade 4

1.10

(0.70–1.74)

0.67

1.04

(0.66–1.64)

0.87

Age, years

 <70

1 (Reference)

  

1 (Reference)

  

 ≥70

1.01

(0.89–1.15)

0.89

1.08

(0.95–1.23)

0.26

Sex

 Male

1 (Reference)

  

1 (Reference)

  

 Female

0.82

(0.73–0.93)

0.0012

0.85

(0.75–0.96)

0.0071

BMI, kg/m2

 18.5–25

1 (Reference)

  

1 (Reference)

  

 <18.5

0.99

(0.83–1.17)

0.88

0.96

(0.81–1.15)

0.67

 25>

1.09

(0.93–1.27)

0.29

1.07

(0.91–1.25)

0.40

PS (ECOG)

 0

1 (Reference)

  

1 (Reference)

  

 1, 2

0.82

(0.58–1.15)

0.26

0.83

(0.59–1.17)

0.29

Tumour location

 Colon

1 (Reference)

  

1 (Reference)

  

 Rectum

1.39

(1.23–1.56)

<0.0001

1.55

(1.37–1.74)

<0.0001

Histology

 Well to moderate

1 (Reference)

  

1 (Reference)

  

 Other

1.44

(1.17–1.76)

0.0005

1.28

(1.04–1.57)

0.019

pT-stagea

 T1–3

1 (Reference)

  

1 (Reference)

  

 T4

1.71

(1.51–1.92)

<0.0001

1.88

(1.67–2.13)

<0.0001

pN-stagea

 N0

1 (Reference)

  

1 (Reference)

  

 N1

1.75

(1.41–2.17)

<0.0001

2.37

(1.90–2.95)

<0.0001

 N2

3.23

(2.58–4.04)

<0.0001

3.94

(3.14–4.94)

<0.0001

  1. CI confidence interval, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, UICC Union for International Cancer Control, Well to moderate well or moderately differentiated.
  2. aThe pathological T-stage and N-stage are based on UICC version 6.
Back to article page